Gretchen A. Gignac MD
Clinical Associate Professor, Hematology & Medical Oncology
820 Harrison Ave | (617) 638-2361gignacg@bu.edu
gretchen.gignac@bmc.org

Sections
Hematology & Medical Oncology
Centers
BU-BMC Cancer Center
Evans Center for Interdisciplinary Biomedical Research
Biography
I am a medical oncologist who has clinical and research expertise in genitourinary medical oncology as well as clinical trials. My clinical practice is at Boston Medical Center and includes adult patients with cancers of the prostate, kidney, bladder, testicles and penis, as well as other solid cancers. My treatment expertise is in hormonal agents, chemotherapy, immunotherapy, targeted therapies, radioactive pharmaceuticals, bone targeted therapies, supportive and palliative care. I am also an educator in the Chobanian and Avedisian School of Medicine and Boston Medical Center Hematology and Oncology Fellowship Program.
Education
MD, University of Pennsylvania School of Medicine
BA, University of Rochester
Publications
Zayhowski K, Wang C, Nahorniak M, Loo S, Gignac G, Gunn C. A qualitative study of the experiences of patients with prostate cancer when receiving negative genetic results: "I still don't have a grasp of what it all means". J Genet Couns. 2024 Nov 29. PMID: 39611226.
Published on 3/12/2024Khosla H, Bhatt S, Wang MJ, Gignac G, Mittal K, Patel J. Enfortumab-vedotin use for urothelial carcinoma in two patients on hemodialysis. J Oncol Pharm Pract. 2024 Jul; 30(5):941-944. PMID: 38470473.
Published on 6/29/2023Gunn CM, Gignac G, Hardy B, Zayhowski K, Pankowska M, Loo S, Wang C. Characterizing Referrals for Prostate Cancer Genetic Services in a Safety-Net Hospital. JCO Oncol Pract. 2023 Oct; 19(10):852-859. PMID: 37384869.
Published on 1/1/2023Gunn CM, Li EX, Gignac GA, Pankowska M, Loo S, Zayhowski K, Wang C. Delivering Genetic Testing for Patients with Prostate Cancer: Moving Beyond Provider Knowledge as a Barrier to Care. Cancer Control. 2023; 30:10732748221143884. PMID: 36946278.
Published on 11/4/2022Jafari N, Chen A, Kolla M, Pompa IR, Qiu Y, Yu R, Llevenes P, Ennis CS, Mori J, Mahdaviani K, Halpin M, Gignac GA, Heaphy CM, Monti S, Denis GV. Novel plasma exosome biomarkers for prostate cancer progression in co-morbid metabolic disease. Adv Cancer Biol Metastasis. 2022 Dec; 6. PMID: 36644690.
Published on 6/16/2022Quintiliani LM, Murray GF, Waite K, Salerno K, Gignac GA, Yuh D, Volandes A, Paasche-Orlow MK. "I'm in My Feelings Now": Examination of Advance Care Planning Video Declarations by People with Advanced Cancer from a Safety Net Hospital. J Palliat Med. 2023 Jan; 26(1):28-34. PMID: 35708552.
Published on 4/11/2022Mori JO, Shafran JS, Stojanova M, Katz MH, Gignac GA, Wisco JJ, Heaphy CM, Denis GV. Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins. Prostate. 2022 Jun; 82(10):1005-1015. PMID: 35403746.
Published on 2/22/2020Chua S, Qureshi MM, Boyd G, Gignac GA, Hirsch AE. Outcomes for Young Men With Localized Intermediate-Risk Prostate Cancer: An Analysis of the NCDB. Clin Genitourin Cancer. 2020 10; 18(5):e531-e542. PMID: 32220567.
Published on 6/13/2018Karantanos T, Karanika S, Seth B, Gignac G. The absolute lymphocyte count can predict the overall survival of patients with non-small cell lung cancer on nivolumab: a clinical study. Clin Transl Oncol. 2019 Feb; 21(2):206-212. PMID: 29948974.
Published on 12/13/2017Kan CK, Qureshi MM, Gupta A, Agarwal A, Gignac GA, Bloch BN, Thoreson N, Hirsch AE. Risk factors involved in treatment delays and differences in treatment type for patients with prostate cancer by risk category in an academic safety net hospital. Adv Radiat Oncol. 2018 Apr-Jun; 3(2):181-189. PMID: 29904743.
Media Mentions
Published on 4/7/2023
761 exceptional women in oncology, per Castle Connolly
View full list of 1 media mentions.